Razelle Kurzrock, MD
Razelle Kurzrock, MD
Distinguished Professor of Medicine, UC San Diego School of Medicine
Verified email at ucsd.edu
Cited by
Cited by
The biology of chronic myeloid leukemia
S Faderl, M Talpaz, Z Estrov, S O'Brien, R Kurzrock, HM Kantarjian
New England Journal of Medicine 341 (3), 164-172, 1999
PD-L1 expression as a predictive biomarker in cancer immunotherapy
SP Patel, R Kurzrock
Molecular cancer therapeutics 14 (4), 847-856, 2015
Phase II trial of curcumin in patients with advanced pancreatic cancer
N Dhillon, BB Aggarwal, RA Newman, RA Wolff, AB Kunnumakkara, ...
Clinical cancer research 14 (14), 4491-4499, 2008
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ...
Molecular cancer therapeutics 16 (11), 2598-2608, 2017
The molecular genetics of Philadelphia chromosome–positive leukemias
R Kurzrock, JU Gutterman, M Talpaz
New England Journal of Medicine 319 (15), 990-998, 1988
Epstein-Barr virus and cancer
MP Thompson, R Kurzrock
Clinical cancer research 10 (3), 803-821, 2004
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ...
The Lancet 379 (9829), 1893-1901, 2012
Autophagy as a target for anticancer therapy
F Janku, DJ McConkey, DS Hong, R Kurzrock
Nature reviews Clinical oncology 8 (9), 528-539, 2011
Clinical toxicity of interferons in cancer patients: a review.
JR Quesada, M Talpaz, A Rios, R Kurzrock, JU Gutterman
Journal of Clinical Oncology 4 (2), 234-243, 1986
Liposome‐encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
L Li, FS Braiteh, R Kurzrock
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
Chronic myelogenous leukemia: a concise update
HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz
Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate
S Kato, A Goodman, V Walavalkar, DA Barkauskas, A Sharabi, ...
Clinical Cancer Research 23 (15), 4242-4250, 2017
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ...
Journal of Clinical Oncology 29 (19), 2660, 2011
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
N Krishnamurthy, R Kurzrock
Cancer treatment reviews 62, 50-60, 2018
Philadelphia chromosomepositive leukemias: from basic mechanisms to molecular therapeutics
R Kurzrock, HM Kantarjian, BJ Druker, M Talpaz
Annals of internal medicine 138 (10), 819-830, 2003
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ...
The lancet oncology 13 (8), 782-789, 2012
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients
M Talpaz, H Kantarjian, R Kurzrock, JM Trujillo, JU Gutterman
Annals of internal medicine 114 (7), 532-538, 1991
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ...
Clinical cancer research 18 (22), 6373-6383, 2012
Sweet's syndrome revisited: a review of disease concepts
PR Cohen, R Kurzrock
International journal of dermatology 42 (10), 761-778, 2003
Interleukin‐6 and its receptor in cancer: implications for translational therapeutics
DS Hong, LS Angelo, R Kurzrock
Cancer 110 (9), 1911-1928, 2007
The system can't perform the operation now. Try again later.
Articles 1–20